TRIAL DETAIL

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Drug:
Trial Name:
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Terminated
Phase:
3
Start Date 05/20/2009
Age of Trial (yrs) 13.1
Treatment Phase:
Stable Disease
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
EORTC 62063
Sponsor:
EORTC AGITG FSG ISG SSG
Patient Contact:
Anne Kirkpatrick Project Manager - EORTC, Brussels, Belgium anne.kirkpatrick@eortc.be +32 2 7741691
Contact email:
Contact Phone:
Randomized:
Randomized
IV or Oral:
Oral
Trial Notes:
The contacts are either Anne Kirkpatrick at EORTC +32 2 7741691 or Allesandro Gronchi The Trial Coordinator at +39 02 23903234. Sites listed are not a complete list.

Participating Groups:
EORTC Soft Tissue and Bone Sarcoma Group(Coordinating Group)
Australasian Gastro-Intestinal Trials Group
French Sarcoma Group
Italian Sarcoma Group
Scandinavian Sarcoma Group

Alessandro Gronchi (Study Coordinator) - Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milano
Martine Van Glabbeke (Statistician) - EORTC, Brussels
Catherine Hermans (Data Manager) - EORTC, Brussels
Sandrine Marreaud (Coordinating Physician) - EORTC, Brussels

Trial Links

 
 
 
 

Trial Results

Drug Information

All About Gleevec (LRG website)
 
Gleevec prescribing information
 
Patient assistance program (insurance, financial help, etc).
 
Gleevec blood level monitoring (LRG story/info)
 
Gleevec drug interactions (LRG site)
 
Gleevec.com website (GIST portion)
 
FDA approves adjuvant Gleevec
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
 
Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment
 
European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients
 
Disintegration of chemotherapy tablets (including imatinib) for oral administration in patients with swallowing difficulties
 
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
 

Trial Sites

Name
Address
City
State
Zip
Country
Amsterdam
1066 CX
Netherlands
10 St Andrews Place
East Melbourne
Victoria
3002
Australia
Villejuif
Val de Narne
94805
France
28 rue Laennec
Lyon
Rhone
69373
France
229 Cours Argonne
Bordeaux
Gironde
33076
France
Nantes
France
via Giacomo
Milan
20133
Italy
Leiden
2333
Netherlands
Nijmegen
Gelderland
6525 GH
Netherlands
London
NW1 2PG
UK
550 Wilmslow Rd
Manchester
Lancashire
M20 4BX
UK
Marseille
13000
France